|Day Low/High||175.30 / 177.91|
|52 Wk Low/High||155.02 / 427.70|
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, October 31, 2019, the Company will release financial results for the second quarter of fiscal 2020.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abiomed, Inc.
Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, announces the 1,000th patient has been treated with the Impella heart pump in Japan.
Data presented today from the National Cardiogenic Shock Initiative Study (NCSI) on 250 consecutive AMI cardiogenic shock (AMICS) patients from 49 sites demonstrates 72% survival at discharge with 98% native heart recovery.
Abiomed (NASDAQ: ABMD) announces the results of PROTECT III, the ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.
Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against ABIOMED, Inc.
The highest court in Germany, the Federal Court of Justice, recently ruled in favor of Abiomed (NASDAQ: ABMD) in a patent challenge filed by Thoratec in 2015 and validated the strengths of Abiomed's Impella-related patents.
NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Abiomed, Inc.
Abiomed (NASDAQ:ABMD) will highlight the benefits of complete revascularization with Protected PCI and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients at the 31 st Transcatheter...
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R.
NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ABIOMED, Inc.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: None Downgrades: ABMD, ATI, BWA, CRM, IFF, LBRT, NBEV, SFIX, VIA Initiations: BJ, EVSI, ONE Read on to get TheStreet Quant Ratings' detailed report:
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abiomed, Inc.
Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming October 7, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Abiomed, Inc.
NEW YORK, Aug. 9, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Abiomed, Inc.
NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abiomed, Inc.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Abiomed, Inc.
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Abiomed, Inc.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc.
NEW YORK, Aug. 7, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of shareholders of Abiomed, Inc.
NEW YORK, Aug. 7, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Abiomed, Inc.
NEW YORK, Aug. 6, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abiomed, Inc.
New training programs, organizational changes in distribution, and certain external initiatives implemented in the first quarter 'will require time to drive more growth,' the CEO says.
ABMD has been one of the best-performing stocks in the S&P 500 over the past five years.
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 1, 2019, the Company will release financial results for the first quarter of fiscal 2020.
Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.
Abiomed's (NASDAQ:ABMD) Impella platform is being featured today at a Washington, D.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.